Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

Huang, He; Li, Xueying; Zhu, Jun; Ye, Sheng; Zhang, Hongyu; Wang, Wei; Wu, Xiangyuan; Peng, Jiewen; Xu, Bing; Lin, Yingcheng; Cao, Yabing; Li, Haoran; Lin, Suxia; Liu, Qing; Lin, Tongyu

doi:10.1001/jama.2014.15704

Public

Entecavir vs Lamivudine for Prevention of Hepatitis B Virus Reactivation Among Patients With Untreated Diffuse Large B-Cell Lymphoma Receiving R-CHOP Chemotherapy

Published in JAMA • Dec 16, 2014

Authors:

He Huang

Xueying Li

Jun Zhu

Abstract

IMPORTANCE: Hepatitis B virus (HBV) reactivation is a serious complication for patients with lymphoma treated with rituximab-containing chemotherapies, despite lamivudine prophylaxis treatment. An optimal prophylactic antiviral protocol has not been determined. OBJECTIVE: To compare the efficacy of ...

Subject

Entecavir

Medicine

Lamivudine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!